<DOC>
	<DOCNO>NCT00511485</DOCNO>
	<brief_summary>This Phase II clinical trial evaluate benefit therapy vintafolide participant progressive adenocarcinoma lung .</brief_summary>
	<brief_title>Study Vintafolide ( MK-8109 , EC145 ) Participants With Progressive Adenocarcinoma Lung ( MK-8109-008 , EC-FV-03 )</brief_title>
	<detailed_description>This Phase II clinical trial vintafolide administer participant progressive adenocarcinoma lung . Vintafolide drug specifically design enter cancer cell via folate vitamin receptor ( FR ) . Experimental evidence show target receptor express significant portion non-small cell lung cancer . Early clinical evidence small number Phase I patient suggest vintafolide generally well-tolerated , without many side-effects observe more-standard therapeutic agent . This evidence suggest vintafolide may useful chemotherapy progressive adenocarcinoma lung . The primary objective study collect data clinical benefit produce therapy vintafolide . All participant undergo image FR target investigational imaging agent etarfolatide ( EC20 , FolateScan ) screen period confirm eligibility treatment portion clinical trial . Clinical evidence suggest etarfolatide may use identify patient cancer express target receptor . Information safety tolerability vintafolide etarfolatide assess .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vinca Alkaloids</mesh_term>
	<criteria>Advanced , progressive , adenocarcinoma lung . Previously receive least 2 cytotoxic contain chemotherapeutic regimen ( include epidermal growth factor receptor [ EGFR ] inhibitor ) . There upper limit number prior chemotherapeutic regimen . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . At least 4 week prior therapy recover associate acute toxicity . Radiographic evidence measurable disease ertafolide `` positive '' tumor . Adequate bone marrow reserve , hepatic , renal function . Negative serum pregnancy test woman childbearing potential willingness practice contraceptive method . Serious comorbidities ( determine Principal Investigator ) . History carcinomatous peritonitis . History severe bowel obstruction ( determine Principal Investigator ) . Women pregnant lactating . Prior radiation therapy assessable disease , unless disease progression confirm site . Participants require palliative radiotherapy time study entry . Note : Participants central nervous system ( CNS ) metastasis eligible ) treat CNS metastasis clinically stable ( regard CNS disease ) &gt; 4 week b ) require steroid antiseizure medication ( i.e. , seizure control ) , CNS metastasis untreated date , associate midline shift significant edema clinicallyevident requirement steroid antiseizure medication . In either situation , participant must steroids and/or antiseizure medication least 14 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Phase II</keyword>
	<keyword>Lung</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>EC145</keyword>
	<keyword>EC20</keyword>
</DOC>